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Background: The Patient Protection and Affordable Care Act of 2010 (ACA) added preventive
services for women, recommended by the IOM, to healthcare coverage requirements beginning in
August 2011.
Purpose: The current review provides evidence on the economic impact of services that will be
covered under the ACA, focusing on IOM-recommended measures that address women’s health.
Methods: This review analyzed the cost-effectiveness literature related to these services using the
Tufts Medical Center Cost-Effectiveness Analysis Registry (www.cearegistry.org), which catalogs
detailed information on cost-effectiveness studies published in English in the peer-reviewed litera-
ture. In order to keep the review relevant to current clinical practice, the analysis was restricted to
studies published in 2000–2010. The data search and analysis were performed in 2011.
Results: Cost-effectiveness studies have evaluated a limited subset of the preventive measures
available for women. Further, few cost-effectiveness studies have evaluated the recommended
counseling and screening services for women. Of 16 relevant studies found, eight focused on HIV
screening, with results varying substantially depending on the specifıc groups screened and the
screening frequency.
Conclusions: The current reviewunderscores the fınding that there is a substantial gap in the health
economic literature on preventive care, especiallywith respect to screening and counseling ofwomen
in the primary care setting. There is some evidence that better access to preventive services can be
maintained at a reasonable cost to the healthcare system, and that certain services may even lower
healthcare costs.
(Am J Prev Med 2013;44(1S1):S12–S15) © 2013 American Journal of Preventive MedicinegBackground
ThePatient Protection and Affordable Care Act of2010 (ACA) added requirements for health plansto cover a range of clinical preventive services
ithout cost-sharing in order to increase access to and
tilization of such services. In August 2011, preventive
ervices for women, recommended by the IOM, were
dded to coverage requirements under the ACA. Policy-
akers have a heightened interest in promoting preven-
ive services, due at least in part to a belief that more
reventive care will help address the nation’s healthcare
ost problem.1 However, previous research has found that
lthough preventive services typically improve health in
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S12 Am J Prev Med 2013;44(1S1):S12–S15 © 2013 Amereneral, they do not necessarily lower healthcare costs.1,2
In developing their recommendations, the IOM commit-
tee explicitly chose not to factor in cost-effectiveness
information.3
The current review provides evidence on the economic
impact of services that will be covered under the ACA,
focusing on IOM-recommended measures that address
women’s health (Table 1). The review discusses how cost-
effectiveness data might be used to improve society’s
investment in health care. Further discussion focuses on
future research that could help decision makers evaluate
policies promoting prevention, and identify opportuni-
ties to increase effıciency and value in the healthcare
system.
The ACAmade important strides in ensuring broader
and more-universal access to preventive services for
women. The services listed in Table 1 may have already
been available in some health plans. However, not all of
the plans comprehensively covered these services, and
those that did often imposed a patient copayment or
some type of cost-sharing.
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A cost-effectiveness analysis quantifıes value as the ratio of an
intervention’s incremental costs to its incremental benefıts, typi-
cally measured in terms of quality-adjusted life-years (QALYs)
saved. The cost-effectiveness ratio represents the “price” of the
accrued health benefıts (dollars expended per QALY gained): low
values are favorable because they indicate that the intervention
accrues health benefıts at low cost. An intervention with a low ratio
may be referred to as cost-effective. An intervention is considered
cost-saving if it offsets medical costs in excess of its own costs.
Finally, some interventions can worsen health while increasing
costs.
This review analyzed the contents of the Tufts Medical Center
Cost-Effectiveness Analysis Registry (www.cearegistry.org), which
catalogs detailed information on cost-effectiveness studies pub-
lished in English in the peer-reviewed literature. Each article
catalogued in the registry estimates the cost-effectiveness (in
terms of incremental cost per QALY gained) of one or more
interventions. At the time of the current analysis, the registry
included articles published from 1976 through 2010, and the
analysis included all articles published in the most recent 10
years, from 2000 to 2010. Of more than 2600 original studies,
426 focused on primary prevention interventions, designed to
Table 1. Additional women’s health clinical preventive
services required per IOM recommendations
Service Description
Well-woman visits Annual preventive care visit for
adult women
Gestational diabetes
screening
Screening in women who are
24–28 weeks pregnant and
those at high risk of
developing gestational
diabetes
HPV DNA screening Screening every 3 years for high-
risk HPV, regardless of Pap
results, in women aged 30
years
Counseling on sexually
transmitted
infections
Annual counseling for sexually
active women
HIV screening and
counseling
Annual screening and counseling
for sexually active women
Contraception and
contraceptive
counseling
FDA-approved contraceptive
methods, sterilization
procedures, and patient
education and counseling
Breastfeeding support,
supplies, and
counseling
Pregnant and postpartum women
will have access to
comprehensive lactation
support and counseling from
trained providers, as well as
breastfeeding equipment
Domestic violence
screening
Screening and counseling for
interpersonal and domestic
violence for all women
FDA, U.S. Food and Drug Administration; HPV, human papillomavirusvert the onset of a disease.
anuary 2013The data search and analysis were performed in 2011. The
nalysis searched for studies that specifıcally evaluated the clin-
cal services outlined in Table 1. These services, as recom-
ended by the IOM,3 include an annual “well-woman” preven-
tive care visit, screening for gestational diabetes in pregnant
women, human papillomavirus (HPV) DNA screening begin-
ning at age 30 years; annual counseling on sexually transmitted
infections (STIs); and annual counseling and screening for HIV
infection. Services recommended by the IOM also include con-
traceptive methods, procedures, and patient education and
counseling; breastfeeding support and counseling, including the
costs of breastfeeding equipment, such as breast pumps; and
screening and counseling for interpersonal and domestic
violence.
Results
Table 2 summarizes the current fındings. Cost-effectiveness
studies have evaluated a limited subset of the preven-
tive measures available for women. Further, few cost-
effectiveness studies have evaluated the recommended
counseling and screening services for women. In par-
ticular, no published cost-utility study has evaluated
breastfeeding support and provision of breast pumps
to women in the general population, although one
study from the United Kingdom (UK) found that en-
hanced contact from in-hospital staff, to support
breastfeeding for low–birth weight infants, was
cost-saving.
Further, no studies evaluated a primary physician
visit for the purpose of preventive services for women.
Two studies evaluated gestational diabetes screening
in pregnant women and found it to be cost-saving or
cost-effective, depending on the specifıc screening test.
One study evaluated various methods of contraception
and found them cost-saving over a fairly short time
frame. One study from the UK found that screening
women for domestic violence as part of their primary
care contact was cost-effective.
In contrast, eight studies evaluated the cost-effectiveness
of HIV screening, with results varying substantially
depending on which specifıc groups were screened and
on the screening frequency. Screening tended to be more
economically favorablewhen it targeted populationswith
risk factors or higher disease prevalence, or when screen-
ing was performed less frequently. Only one study evalu-
ated counseling for prevention of sexually transmitted
diseases in general, and it found counseling sessions
with urban women to be moderately cost-effective.
Finally, two studies evaluated HPV DNA screening in
adult women and reported generally favorable cost-
effectiveness ratios ranging from $10,000 to $59,000/
QALY, depending on the age groups targeted and the
screening protocols used.
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A previous study4 found
hat published cost-
ffectiveness research
as not covered certain
mportant areas in health
are, and these issues re-
ain unresolved. The
urrent review under-
cores the fınding that
here is a substantial gap
n the health economic
iterature on preventive
are, especially with re-
pect to screening and
ounseling of women in
he primary care setting.
n addition, even though
here have been thou-
ands of publications on
reastfeeding and renewed efforts in the U.S. to encour-
ge breastfeeding, there is a conspicuous lack of cost-
ffectiveness analyses (at least in the form of cost per
ALY) in this area.
Studies that this review did identify often indicate that
ost of the recommended services provide good value,
nd some (e.g., contraceptive interventions or gestational
iabetes screening) may even save money. However,
hese fındings must be viewed with caution because they
re based on individual studies and have not been repli-
ated. The current study shows that there are still many
reas where further research on cost-effectiveness is nec-
ssary. A further review of all the preventive services
overed by the ACA will shed further light on additional
reas for cost-effectiveness research.
Over time, as technologies and understanding of dis-
ases evolve, it will be important to re-evaluate society’s
nvestment in specifıc clinical services, especially those
rovided to patients without cost-sharing to remove any
conomic barriers to access. One key tool will be contin-
ed work in the area of comparative-effectiveness re-
earch (CER). Interventions should be evaluated in the
ontext of the relevant patient population, clinical setting,
nd treatment alternatives. Economic analysis should be
part of the evaluation, as continued cost pressures make
t imperative to focus on improving value,meaning the ratio
f dollars spent to clinical benefıt accrued.
In addition to noting the economic impact of clinically
ffective preventive services, a positive step would be to
dentify highly cost-effective preventive services not uti-
ized at levels that would improve health at a reasonable
ost for large populations. As the current research shows,
Table 2. Cost effectiveness
Measure
Well-woman visits
Gestational diabetes screen
HPV DNA screening
STI counseling
HIV screening and counselin
Contraception and
contraceptive counseling
Breastfeeding support,
supplies, and counseling
Domestic violence screenin
aIncremental cost per QALY rat
HPV, human papillomavirus; NA
infectionhere are gaps and limitations in the cost-effectiveness andCER literature that must be addressed for policymakers to
make well-informed decisions. Ideally, a systematic effort
would review preventive services and evaluate both health
outcomes andcost-effectiveness.A subsequent studyof cur-
rent service utilization levels and a model analyzing the
impact of changes in utilization rates could provide useful
insights into how investments in specifıc servicesmay influ-
ence health outcomes and resource utilization.
It is not surprising that fewer cost-effectiveness studies
have evaluated preventive services than pharmaceuticals
or medical devices. For one, there is more funding avail-
able for pharmaceutical and medical device research. In
addition, there has long been demand from healthcare
payers, among others, for economic evidence for drugs
and devices. Manufacturers of new technologies for the
most part have funded development of this evidence.
Because prevention, primary care, or counseling often
does not involve a specifıc high-priced technology, there
has been no clear demand for economic or even clinical
evidence.With the establishment of agencies dedicated to
patient-centric, rather than technology-centric CER, the
authors hope that more such interventions and services
will be studied and evaluated.
Policy recommendations to use cost-effective and ben-
efıcial preventive services will not by themselves be suffı-
cient. Ensuring the availability and use of these services
by those patients who would benefıt will also depend on
implementing appropriate incentives. One piece of the
puzzle is patient fınancial burden: Studies have linked
utilization with patient copay levels for services ranging
frompharmaceuticals to preventivemeasures. Preventive
services in particular may suffer from unanticipated in-
OM-recommended clinical preventive services for women
$/QALY rangea References
NA
Cost-saving (vs no screening) 5, 6
10,000–59,000 7, 8
12,000–44,000 9
7,300–640,000 (depending on specific
population and screening frequency)
10–17
Cost-saving 18
NA (enhanced staff contact to promote
breastfeeding for low–birth weight
infants; cost-saving)
19
5,000 20
ave been converted to 2010 U.S. dollars.
available; QALY, quality-adjusted life-year; STI, sexually transmittedof I
ing
g
g
ios h
, notcentives created by existing reimbursement systems (e.g.,
www.ajpmonline.org
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Jcopayments that discourage their use). Ensuring that in-
centives from all relevant perspectives encourage the best
long-term health care for all individuals will require care-
ful examination of how care is coordinated, delivered,
and reimbursed.
After initial coverage decisions are made, it is also
important to continue to monitor preventive services
outcomes. Often, studies are based on models that ex-
trapolate clinical trial fındings. These fındingsmay not be
borne out in realistic settings, where patient populations
andmany other factorsmay differ from those in a clinical
trial. As services become more broadly used by patients,
observational data emerge that can be used to evaluate the
impact of these services on health, medical resource use,
and costs. For instance, Medicare claims data have long
been used to gauge treatment patterns and costs in many
clinical areas. As standards and practice of electronic
medical records stabilize and become, if not universal, at
least interoperable, researchers will be able to meaning-
fully study many more patient populations across more
types of settings and funding sources—not limited to
those who are covered by private insurance or the Medi-
care and Medicaid programs.
There is much work ahead. Growing awareness and
means for careful study of preventive services can provide
decision makers with valuable information. There is
some evidence that better access to preventive services
can be maintained at a reasonable cost to the healthcare
system, and that certain services may even lower health-
care costs.
Publication of this article was supported by the West Health
Initiative.
No fınancial disclosures were reported by the authors of this
paper.
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